Brook Byers

Axys Pharmaceuticals, Inc. engages in the development of integrated drugs. The company is headquartered in South San Francisco, CA.

Hybritech, Inc. provides prostate diagnostic testing services. The company is headquartered in San Diego, CA.

Signal Pharmaceuticals Inc is pioneering the discovery and development of small molecule therapeutics which regulate the transcription factors involved in the progression of a number of inflammatory, viral and neurological diseases. The core technology for the company's research was discovered in the laboratories of three of its founders, and has been licensed from the University of California and the Salk Institute. (SB) It was located in San Diego, CA.

Argonaut Technologies, Inc. develops, manufactures, and markets products that enable chemists to use high speed parallel synthesis in the development of new drugs

Gen-Probe, Inc. develops, manufactures and markets rapid, accurate and molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility. It also develops and manufactures the PROCLEIX assays, which are used to detect human immunodeficiency virus, the hepatitis C virus, the hepatitis B virus, and the West Nile virus in donated human blood. The firm's clinical diagnostics products include APTIMA family of assays, which are used to detect the common STDs chlamydia and gonorrhea. Gen-Probe was founded by Thomas H. Adams and David E. Kohne in 1983 and is headquartered in San Diego, CA.

Pharmacopeia LLC develops small molecule therapeutics to address significant medical needs. The firm operates as clinical development stage Biopharmaceutical Company which focuses on discovering and developing novel small molecule therapeutics to address medical needs. The company was founded by John J. Baldwin in February 2002 and is headquartered in Cranbury, NJ.

CardioDx, Inc. operates as a cardiovascular genomic diagnostics firm. It develops proprietary tests that improve treatment decisions and patient outcomes on coronary artery disease, cardiac arrhythmia, and heart failure. The company was founded by David L. Levison and Christopher R. Burrow in 2004 and is headquartered in Redwood, CA.

Genomic Health, Inc. engages in the provision of genomic-based diagnostic tests. Its tests analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. The firm uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning. The company was founded by Patrick F. Terry, Joffre B. Baker, Randal W. Scott, and Steven Shak in August 2000 and is headquartered in Redwood City, CA.

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C.

OptiMedica Corp. manufactures medical devices. It is a ophthalmic device company dedicated to developing technologies that improve patient outcomes. It focuses in the cataract therapeutic area. The company was founded in 2004 and is headquartered in Sunnyvale, CA.

Crescendo Bioscience, Inc. develops and commercializes quantitative blood tests for rheumatoid arthritis and other autoimmune diseases. It develops quantitative, objective, reproducible blood tests to provide rheumatologists with deeper clinical insight to help enable more effective management of patients with autoimmune and inflammatory diseases. The company was founded by Mike B. Centola and Christopher L. Sutton in July 2002 and is headquartered in South San Francisco, CA.

Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients.

Elcelyx Therapeutics, Inc. develops novel therapeutics based on gut sensory modulation. Its product NewMet is being developed for use by type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its use. The firm also provides dietary supplements for weight management. The company was founded by Alain D. Baron in 2010 and is headquartered in San Diego, CA.

Oculeve, Inc. develops devices for dry eye disease treatment. The company was founded by D. Michael Ackermann, Brandon M. Felkins, Garrett Cale Smith and Victor Wayne McCray in 2011 and is headquartered in Parsippany, NJ.

Kleiner Perkins Caufield & Byers LLC (Kleiner Perkins Caufield & Byers) is a venture capital firm founded in 1972 by Eugene Kleiner, Thomas Perkins, Brook Byers and Frank J. Caufield. The firm is headquartered in California, US.

UCSF Medical Center owns and operates hospitals. It operates hospitals in San Francisco as well as satellite facilities. It provides health care facilities to children, organ transplants, cardiac care, fertility treatments, neurosurgery, ophthalmology, and orthopedics. It also provides outpatient care and some programs in areas as women's health, aging, cancer, and pain management. UCSF Medical Center is headquartered in San Francisco, CA.

IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA.

The UCSF Foundation promotes and supports the interests and welfare of the University of California San Francisco and the UCSF Medical Center. The UCSF Foundation’s daily operations are administered by a development staff responsible for major gifts, planned giving, corporate and foundation gifts, annual giving, development communications, alumni relations and campus events

NewSchools Venture Fund provides funds to other non-profit organization that improves public education. It provides education through powerful ideas and passionate entrepreneurs so that all children especially those in underserved communities have the opportunity to succeed. It supports education entrepreneurs, a special breed of innovators who create new nonprofit and for-profit organizations that redefine the sense of what is possible in public education. The company was founded by Brook H. Byers, Kim Smith and Louis John Doerr in and is headquartered in San Francisco, CA.

TechNet operates as the national, bipartisan network of technology CEOs and senior executives that promotes the growth of the innovation economy. The company is headquartered in Washington, DC.

Life Technologies Clinical Services Lab, Inc. offers clinically guided personal genetic testing services for customers. The firm develops and commercializes genetics-based products and services to enhance individual health and wellness; and educates and empowers individuals and their physicians by providing personalized genetic insights about disease risk and medication response to catalyze behavior change and inform clinical decision-making. The company was founded by David B. Agus and Dietrich A. Stephan in 2006 and is headquartered in Foster City, CA.

Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California.

Foundation Medicine, Inc. is a molecular information company, which engages in the provision of information on clinical treatment decisions for patients with cancer. The company was founded on January 10, 2010 and is headquartered in Cambridge, MA.

Newsela, Inc. publishes news articles online. Its common core-aligned quizzes attached to articles give educators and parents insight to student's reading strengths and weaknesses. The company was founded by Matthew Gross and Dan Cogan-Drew in 2013 and is headquartered in New York, NY.

Zephyr Health, Inc. provides cloud-based solutions for health companies. Zephyr health helps life sciences companies organize and visualize global health data to connect their therapies to people in need. It offers medical affairs, marketing, sales and technology solutions. The company was founded by William King in May 2011 and is headquartered in San Francisco, CA.

Verana Health, Inc. engages in the development of software solutions for remote patient monitoring and data analytics. It focuses on bridging the gap between healthcare providers and patients with mobile tests. The company was founded by Mark S. Blumenkranz and Daniel V. Palanker in 2008 and is headquartered in San Francisco, CA.

Enjoy Technology LLC operates a personal commerce platform. It offers mobile store, customer experience, personal commerce, technology, and retail sales. The company was founded by Ronald B. Johnson in 2014 and is headquartered in Menlo Park, CA.

The Life Sciences Foundation engaged in education and biotechnology information dissemination. It collected and organized historical information to educate future innovators, to engage the general public, and to provide lay audiences with an understanding of life sciences and biotechnology. The company was founded by G. Steven Burrill, Dennis Gillings, John Lechleiter, Henri Termeer, and Arnold Thackray in 2010 and was headquartered in San Francisco, CA.

Waycross Ventures LLC (Waycross Ventures) is a venture capital firm founded in 2014. The firm is headquartered in Menlo Park, California.

Octave Bioscience, Inc. operates as an early-stage diagnostics company which provides healthcare services. It focuses on neurodegenerative diseases and conditions. The company was founded by William A. Hagstrom in 2014 and is headquartered in Menlo Park, CA.

GRAIL LLC is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.

Cell Design Labs, Inc. develops disruptive cell-based therapies for cancer and other devastating diseases. The company was founded by Brian G. Atwood and Fred E. Cohen in 2016 and is headquartered in Emeryville, CA.

Epiodyne, Inc. engages in biotechnology services. The company was founded by Brian Shoichet, Brian Kobilka, Peter Gmeiner, Bryan L. Roth, Gregory Scherrer, and Aashish Manglik in 2016 and is headquartered in San Francisco, CA.

Medical Technology Venture Partners (MedTech Venture Partners) is a venture capital firm founded by Radu Cautis and Thomas Heinrich Glanzmann in 2017. The firm is headquartered in San Francisco, California.

Arsenal Biosciences, Inc. discovers, develops, and commercializes curative immune cell therapies. It offers cell therapy, cloud computing, computational biology, genome engineering, machine learning, software engineering, and synthetic immunology. The company was founded by Ken E. Drazan, Bradley E. Bernstein, W. Nicholas Haining, Theo Roth, Kole T. Roybal, and E. John Wherry and is headquartered in San Francisco, CA.